Fair Market Value - Patient Focused Medicines Development

Compensation for Patient Experts at Fair Market Value
Tackling together the patient engagement hot topic

There is no agreed system in place for financial compensation that reflects the level of individual contribution and expertise of patient partners. Do you have an opinion about this topic?
Make your voice heard and contribute now!

Take me to the survey

Why should you contribute

The contribution of patients, patient groups, and patient experts provides tangible value to other stakeholders and society that should be fairly compensated.

Currently, there is no transparent and consistent system in place for financial compensation that reflects the level of individual contribution and expertise of patient partners. But it’s time to change that.

This survey is open to all stakeholders who are relevant to patient engagement and involvement in medicines research, development and delivery phases and lifecycle.

I want to contribute

Next Steps

By completing the questionnaire, you will help create a complete picture of various stakeholder points of view and inform the various projects addressing this issue.

Representatives of the industry including The European Federation of Pharmaceutical Industries and Associations (EFPIA), National Health Council (NHC) and Workgroup of European Cancer Patient Advocacy Networks (WECAN) are already leading the fair market value narrative for patient expertise and PFMD extends its support to synergise their efforts.

Compensation in the context of this survey means honoraria or other payment by third parties (not patient organizations) for individual tasks such as advisory boards, presentations, providing feedback, reviewing complex documents, etc.

Reimbursement of out of pocket expenses such as travel cost, accommodation, meals, etc. do not count as financial compensation for these tasks or for expertise.

I want to contribute

Representatives of the industry including The European Federation of Pharmaceutical Industries and Associations (EFPIA), National Health Council (NHC) and Workgroup of European Cancer Patient Advocacy Networks (WECAN) are already leading the fair market value narrative for patient expertise and PFMD extends its support to synergise their efforts.

X